Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06

Journal of Clinical Oncology

Volumn 27, Issue 25, 2009, Pages 4055-4061

  Efstathiou, Jason A ^a   Bae, Kyounghwa ^a   Shipley, William U ^a   Kaufman, Donald S ^a   Hagan, Michael P ^a   Heney, Niall M ^a   Sandler, Howard M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CYSTECTOMY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PELVIC DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; TRANSURETHRAL RESECTION; TREATMENT INDICATION; UROGENITAL TRACT DISEASE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLADDER TUMOR; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GASTROINTESTINAL DISEASE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RISK; RISK ASSESSMENT; SALVAGE THERAPY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNITED STATES; UROLOGIC SURGERY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LOGISTIC MODELS; MALE; MALE UROGENITAL DISEASES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 70249121114     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.5776     Document Type: Article

References (28)

1. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19:666-675, 2001
2. Gerharz EW, Mansson A, Hunt S, et al: Quality of life after cystectomy and urinary diversion: An evidence based analysis. J Urol 174:1729-1736, 2005
3. Henningsohn L, Steven K, Kallestrup EB, et al: Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol 168:168-174, 2002; discussion 174-5, 2002
4. Kaufman DS, Shipley WU, Griffin PP, et al: Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 329:1377-1382, 1993
5. Rodel C, Grabenbauer GG, Kuhn R, et al: Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 20:3061-3071, 2002
6. Tester W, Porter A, Asbell S, et al: Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25:783-790, 1993
7. Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14:119-126, 1996
8. Shipley WU, Winter KA, Kaufman DS, et al: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16:3576-3583, 1998
9. Kaufman DS, Winter KA, Shipley WU, et al: The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5:471-476, 2000
10. Hagan MP, Winter KA, Kaufman DS, et al: RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twicedaily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57:665-672, 2003
11. Kaufman DS, Winter KA, Shipley WU, et al: Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73:833-837, 2009
12. Shipley WU, Kaufman DS, Zehr E, et al: Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer. Urology 60: 62-67, 2002; discussion 67-68, 2002
13. Hautmann RE, Gschwend JE, de Petriconi RC, et al: Cystectomy for transitional cell carcinoma of the bladder: Results of a surgery only series in the neobladder era. J Urol 176:486-492, 2006; discussion 491-492, 2006
14. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866, 2003
15. Zietman AL, Sacco D, Skowronski U, et al: Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors. J Urol 170:1772-1776, 2003
16. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346, 1995
17. Agresti A: Categorical Data Analysis. Hoboken, NJ, John Wiley & Sons, 2002
18. Cox DR: Regression Models and Life Tables. J R Stat Soc Series B 34:187-229, 1972
19. Gogna NK, Matthews JH, Turner SL, et al: Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol 81:9-17, 2006
20. Rodel C, Weiss C, Sauer R: Organ preservation by combined modality treatment in bladder cancer: The European perspective. Semin Radiat Oncol 15:28-35, 2005
21. Caffo O, Fellin G, Graffer U, et al: Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma: A survey by a self-administered questionnaire. Cancer 78:1089-1097, 1996
22. Henningsohn L, Wijkstrom H, Dickman PW, et al: Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 62:215-225, 2002
23. Lynch WJ, Jenkins BJ, Fowler CG, et al: The quality of life after radical radiotherapy for bladder cancer. Br J Urol 70:519-521, 1992
24. Herman JM, Smith DC, Montie J, et al: Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology 64:69-73, 2004
25. Chauvet B, Lagrange JL, Geoffrois L, et al: Quality of life (QOL) assessment after concurrent chemoradiation for invasive bladder cancer: Preliminary results of a French multicenter prospective study. Int J Radiat Oncol Biol Phys 57:S177, 2003 (suppl; abstr 88)
26. Kachnic LA, Shipley WU, Griffin PP, et al: Combined modality treatment with selective bladder conservation for invasive bladder cancer: Longterm tolerance in the female patient. Cancer J Sci Am 2:79-84, 1996
27. Vistad I, Cvancarova M, Fossa SD, et al: Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: How well do physicians' assessments agree with those of their patients? Int J Radiat Oncol Biol Phys 71:1335-1342, 2008
28. Huschka MM, Mandrekar SJ, Schaefer PL, et al: A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer 109: 787-795, 2007